Is the withdrawal of anti-tumour necrosis factor in inflammatory bowel disease patients in remission feasible without increasing the risk of relapse? Results from the randomised clinical trial of GETECCU (EXIT) .

Chaparro, MGarcía Donday, MRiestra, SVan Domselaar, M.Gisbert, J P2024-02-222024-02-222023https://hdl.handle.net/10641/4075engAtribución-NoComercial-SinDerivadas 3.0 Españahttp://creativecommons.org/licenses/by-nc-nd/3.0/es/Is the withdrawal of anti-tumour necrosis factor in inflammatory bowel disease patients in remission feasible without increasing the risk of relapse? Results from the randomised clinical trial of GETECCU (EXIT) .otheropen access10.1093/ecco-jcc/jjac190.0037